Stay updated with breaking news from Oncoextra Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 […]
Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Stock analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Exact Sciences in a research report issued to clients and investors on Wednesday, August 2nd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $0.83 for the […]
Exact Sciences (NASDAQ:EXAS – Free Report) had its target price increased by Robert W. Baird from $99.00 to $121.00 in a report published on Wednesday, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock. EXAS has been the topic of a number of other reports. Citigroup raised their […]
Exact Sciences (NASDAQ:EXAS – Free Report) had its target price raised by Credit Suisse Group from $75.00 to $90.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. Credit Suisse Group currently has a neutral rating on the medical research company’s stock. Other analysts also recently issued reports about the stock. StockNews.com started […]
Alpha DNA Investment Management LLC acquired a new position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,342 shares of the medical research company’s stock, valued at approximately $1,040,000. Other hedge funds and […]